Skip to main content
Top
Published in: Annals of Hematology 12/2007

01-12-2007 | Original Article

Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi

Authors: Luigi Rigacci, Umberto Vitolo, Luca Nassi, Francesco Merli, Andrea Gallamini, Patrizia Pregno, Isabel Alvarez, Flavia Salvi, Rosaria Sancetta, Antonio Castagnoli, Annibale Versari, Alberto Biggi, Michele Gregianin, Ettore Pelosi, Teodoro Chisesi, Alberto Bosi, Alessandro Levis, On behalf of Intergruppo Italiano Linfomi

Published in: Annals of Hematology | Issue 12/2007

Login to get access

Abstract

In this prospective multicentric study, we investigated the contribution of positron emission tomography (PET) scanning to the staging of Hodgkin’s lymphoma (HL) by computed tomography (CT) and attempted to determine whether it has any impact on therapeutic approach. One hundred eighty six consecutive patients with HL from six Italian centers were enrolled in this study. They were staged with conventional methods; 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET scanning were prospectively compared to CT. CT and FDG-PET stages were concordant in 156 patients (84%) and discordant in 30 patients (16%). PET stage in comparison to CT stage was higher in 27 patients (14%) and lower in 3 patients (1%). The programmed treatment strategy was modified in 11 out of 30 patients (37%) after the definition of final stage. If we considered the 123 CT staged patients with localized stage, ten patients (8%) with a change of stage from localized to advanced after PET evaluation were treated with different strategy. FDG-PET was shown to be a relevant, non-invasive method that supplements conventional procedures and should therefore be used routinely to stage HL, particularly in early stage patients, where a change in stage may modify disease management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Donaldson SS, Hancock SL, Hoppe RT (1999) The Janeway lecture. Hodgkin’s disease-finding the balance between cure and late effects. Cancer J Sci Am 5:325–333PubMed Donaldson SS, Hancock SL, Hoppe RT (1999) The Janeway lecture. Hodgkin’s disease-finding the balance between cure and late effects. Cancer J Sci Am 5:325–333PubMed
2.
go back to reference Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMed Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMed
3.
go back to reference Vinnicombe SJ, Reznek RH (2003) Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1):S42–S55PubMedCrossRef Vinnicombe SJ, Reznek RH (2003) Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1):S42–S55PubMedCrossRef
4.
go back to reference Carrington B (1998) Lymph nodes. In: Husband JE, Reznek RH (eds) Imaging in oncology. Isis Medical Media, Oxford, pp 729–748 Carrington B (1998) Lymph nodes. In: Husband JE, Reznek RH (eds) Imaging in oncology. Isis Medical Media, Oxford, pp 729–748
5.
go back to reference Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433PubMed Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433PubMed
6.
go back to reference Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14:123–130PubMedCrossRef Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14:123–130PubMedCrossRef
7.
go back to reference Rigacci L, Castagnoli A, Dini C, Carpaneto A, Matteini M, Alterini R, Carrai V, Nassi L, Bernardi F, Pieroni E, Bosi A (2005) 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin’s lymphoma: long term results. Oncol Rep 14:1209–1214PubMed Rigacci L, Castagnoli A, Dini C, Carpaneto A, Matteini M, Alterini R, Carrai V, Nassi L, Bernardi F, Pieroni E, Bosi A (2005) 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin’s lymphoma: long term results. Oncol Rep 14:1209–1214PubMed
8.
go back to reference Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Bigi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91:475–481PubMed Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Bigi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91:475–481PubMed
9.
go back to reference Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59PubMedCrossRef Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59PubMedCrossRef
10.
go back to reference Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP (2002) 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma. Mol Imaging Biol 4:105–114PubMedCrossRef Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP (2002) 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma. Mol Imaging Biol 4:105–114PubMedCrossRef
11.
go back to reference Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 86:266–273PubMed Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 86:266–273PubMed
12.
go back to reference Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, Shi R, Lilien DL (2004) Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin’s disease. Ann Oncol 15:1699–1704PubMedCrossRef Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, Shi R, Lilien DL (2004) Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin’s disease. Ann Oncol 15:1699–1704PubMedCrossRef
13.
go back to reference Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J, Kuhnel G, Hanel M, Laniado M, Kotzerke J, Ehninger G (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 90:620–625PubMedCrossRef Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J, Kuhnel G, Hanel M, Laniado M, Kotzerke J, Ehninger G (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 90:620–625PubMedCrossRef
14.
go back to reference Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 11:1273–1279PubMedCrossRef Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 11:1273–1279PubMedCrossRef
15.
go back to reference Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era. Ann Oncol 17:117–122PubMedCrossRef Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era. Ann Oncol 17:117–122PubMedCrossRef
16.
go back to reference Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT. Radiology 232:823–829PubMedCrossRef Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT. Radiology 232:823–829PubMedCrossRef
17.
go back to reference Young CS, Young BL, Smith SM (1998) Staging Hodgkin’s disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1:161–164PubMedCrossRef Young CS, Young BL, Smith SM (1998) Staging Hodgkin’s disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1:161–164PubMedCrossRef
18.
go back to reference Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D’Amore F, Boesen AM, Roemer L, Specht L (2006) Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91:482–489PubMed Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D’Amore F, Boesen AM, Roemer L, Specht L (2006) Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91:482–489PubMed
19.
go back to reference Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, Timothy AR (1998) Detection of lymphoma in bone marrow by whole body positron emission tomography. Blood 91:3340–3346PubMed Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, Timothy AR (1998) Detection of lymphoma in bone marrow by whole body positron emission tomography. Blood 91:3340–3346PubMed
20.
go back to reference Pakos EE, Fotopoulos A, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMed Pakos EE, Fotopoulos A, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMed
21.
go back to reference Kaplan LD (2002) Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care. Am J Med 112:262–268CrossRef Kaplan LD (2002) Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care. Am J Med 112:262–268CrossRef
22.
go back to reference Kumar R, Maillard I, Schuster SJ, Alavi A (2004) Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin’s and non-Hodgkin’s lymphomas. Radiol Clin North Am 42:1083–1100PubMedCrossRef Kumar R, Maillard I, Schuster SJ, Alavi A (2004) Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin’s and non-Hodgkin’s lymphomas. Radiol Clin North Am 42:1083–1100PubMedCrossRef
23.
go back to reference Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074PubMedCrossRef Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074PubMedCrossRef
24.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Dihel V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Dihel V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRef
Metadata
Title
Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi
Authors
Luigi Rigacci
Umberto Vitolo
Luca Nassi
Francesco Merli
Andrea Gallamini
Patrizia Pregno
Isabel Alvarez
Flavia Salvi
Rosaria Sancetta
Antonio Castagnoli
Annibale Versari
Alberto Biggi
Michele Gregianin
Ettore Pelosi
Teodoro Chisesi
Alberto Bosi
Alessandro Levis
On behalf of Intergruppo Italiano Linfomi
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0356-9

Other articles of this Issue 12/2007

Annals of Hematology 12/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.